BioMarin acquires enzyme replacement therapy developer ZyStor
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceutical has acquired ZyStor Therapeutics, a privately held US biotechnology company developing enzyme replacement therapies (ERTs) for the treatment of lysosomal storage disorders. ZyStor's lead product candidate, ZC-701 for the treatment of Pompe disease, is slated to enter the clinic next year.